

# Clinical recommendations

## Cancer, fertility and pregnancy: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

G. Pentheroudakis<sup>1</sup>, N. Pavlidis<sup>1</sup> & M. Castiglione<sup>2</sup>  
On behalf of the ESMO Guidelines Working Group\*

<sup>1</sup>Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece; <sup>2</sup>Institute of Social and Preventive Medicine (ISPM), University of Geneva, Geneva, Switzerland

### incidence

The estimated incidence of cancer diagnosed in pregnant women in developed societies is 1:1000 pregnancies and is predicted to rise as childbearing is shifted towards the late reproductive age. The most common cancers associated with pregnancy are cervical, breast cancer, melanoma, lymphomas and acute leukemias (Table 1).

### diagnosis and staging

The diagnostic work-up should include a thorough physical examination, including the pelvis, breasts, lymph nodes, skin and should limit unnecessary exposure to ionizing radiation. Fine needle aspiration, core needle or open excisional biopsies are safe to perform. Chest X-ray and mammography with abdominal shielding and ultrasonic examinations are the cornerstone of a basic staging, supplemented by MRI scans in the second/third trimesters when needed [IV, B]. In view of the theoretical risk of fetal heating/cavitation, first trimester MRI scans should be done sparingly and the potentially teratogenic gadolinium should not be administered [V, D]. Computerized tomography or radioisotope studies should be avoided. Minor staging procedures (spinal tap, bone marrow biopsy, endoscopies) are relatively safe to perform [IV, B].

### risk assessment

Ionizing radiation and cytotoxic agents have potential mutagenic, teratogenic and carcinogenic effects for the embryo, depending on dose, nature of compound, treatment field and gestational stage (Table 2).

Fetal exposure to radiation doses in excess of 5–10 cGy should be avoided. This threshold dose is associated with a very low risk of stochastic biologic effects (mutations) and does not cause non-stochastic effects (malformations, developmental disorders). Exposure to antineoplastic agents should be avoided during the first trimester (organogenesis).

### treatment and follow-up

The optimal therapeutic strategy should be jointly chosen by the medical team, patient and family and will depend on gestational age, nature and stage of cancer, treatment options and patient wishes. The medical team should include an obstetrician, a neonatologist, a medical oncologist, a surgeon and a psychologist and the patient should be treated at major hospitals with the required expertise and infrastructure.

Pregnancy termination is advised in the case of chemotherapy or radiotherapy administration during the first trimester, need for radical gynecologic surgery, poor maternal life expectancy.

### cytotoxic chemotherapy

Chemotherapy can be administered during the second and third trimesters with reasonable safety, though there is an increased risk of still birth, growth retardation and premature delivery [III, B]. Older-generation alkylators (thiotepa, busulfan, chlorambucil, nitrogen mustard) and antimetabolites (aminopterin, methotrexate) have the most pronounced teratogenic and abortive potential, while anthracyclines, 5-fluorouracil, cytarabine and vinca alkaloids the least. Emerging evidence from a small number of case reports suggests that taxanes and platinum compounds are relatively safe to administer beyond the first gestational trimester [IV, C]. There are no data on pemetrexed, gemcitabine, vinorelbine.

### targeted agents

Only a few pregnant women have inadvertently been exposed to targeted agents. Trastuzumab caused oligohydramnios in four and abnormal implantation in one out of seven pregnant women, while rituximab only caused transient neonatal

\*Correspondence to: ESMO Guidelines Working Group, ESMO Head Office, Via L. Taddei 4, CH-6962 Viganello-Lugano, Switzerland;  
E-mail: [clinicalrecommendations@esmo.org](mailto:clinicalrecommendations@esmo.org)

Approved by the ESMO Guidelines Working Group: June 2007, last update November 2008. This publication supersedes the previously published version—Ann Oncol 2008; 19 (Suppl 2): ii108–ii109.

Conflict of interest: the authors have reported no conflicts of interest.

lymphopenia in four reported cases. Imatinib was occasionally associated with low birth weight and premature delivery in 29 reported cases, though one case of hypospadias and one of meningocele have been published as well. In view of lack of data and past experience with the antiangiogenic agent thalidomide, administration of targeted agents modulating angiogenesis (bevacizumab, sunitinib, sorafenib) should be avoided in pregnant women [V, D].

### surgery, radiation therapy and timing of delivery

Delivery should take place after weeks 32–35, 3 weeks after the last chemotherapy cycle. Surgical operations can be safely performed during the first two trimesters, with a slight to moderate increase in the risk of abortion during the first trimester, especially with abdominal operations. In the third trimester, operation or deferral after delivery may be chosen according to circumstances [IV, B]. Radiotherapy should be administered post-partum and care should be taken to avoid fetal exposure to ionizing irradiation of any source to <5–10 cGy [IV, C].

### supportive therapy

Antiemetics (ondansetron, metoclopramide, meclizine) may be safely administered with omission of corticosteroids in the first trimester [II, B]. Analgesics (paracetamol, opioids, anti-inflammatory agents) [IV, B] and growth cytokines [V, D] have been administered in pregnant women beyond the first trimester without untoward effects, though some risk of fetal respiratory depression and ductus arteriosus closure exists. Bisphosphonates and tamoxifen, aromatase inhibitors, somatostatin should be deferred after delivery. Breast feeding should be avoided during chemotherapy.

Although placental/fetal metastases are exceedingly rare, histological examination of the placenta after delivery should take place.

**Table 1.** Incidence of tumor types in pregnant women

Malignancy	Incidence (per no. of gestations)
Malignant melanoma	1:1000–10 000
Breast carcinoma	1:3000–1:10 000
Carcinoma of the cervix	1:2000–10 000
Lymphoma	1:1000–1:6000
Leukemia	1:75 000–1:100 000
Ovarian carcinoma	1:10 000–1:100 000
Colon cancer	1:13 000

**Table 2.** Gestational stage and effects of antineoplastic therapy

Gestational stage	Embryonal/fetal development	Impact
Weeks 0–2	Undifferentiated multicellular organism	'All or nothing', spontaneous abortion or normal development
Weeks 3–12	Organogenesis	Spontaneous abortion, major congenital anomalies
2nd and 3rd trimesters	Intrauterine growth and maturation, continuing development of CNS, gonads, teeth–palate, eyes, ears	Functional defects and minor anomalies of late-forming tissues, still birth, intrauterine growth retardation, premature delivery, myelosuppression

## follow-up

The follow-up of women diagnosed with cancer during pregnancy and their offspring should adhere to common standards. Most cohort studies showed that the outcome of pregnant cancer patients is not significantly inferior to non-pregnant patients matched for age and stage of cancer, though some series reported inferior survival of pregnant women with cancer. Still, it is currently unknown whether the latter finding is due to more aggressive cancer biology during gestation or simply due to undertreatment of these patients.

There is no evidence to establish that patient outcome is compromised by future pregnancies [III, B]. Most cohort studies have shown that women with a history of breast cancer who later become pregnant are at a reduced risk of malignant relapse/death. This finding should be interpreted with caution, as healthy women are the ones who attempt pregnancy, while those who experience a malignant relapse do not.

To date, there is no evidence establishing that *in utero* exposure to chemotherapy (beyond the first trimester) or radiotherapy (doses <10–20 cGy) compromises the long-term physical and mental development of children [IV, B].

Most oncologists would recommend that potentially cured breast cancer patients postpone childbearing for at least 2–3 years, the median time to recurrence for relapsing women.

## fertility preservation

The gonadotoxic effects of ionizing radiation, chemotherapy and surgery depend on patient age, treatment fields, total dose and nature of insulting agents (Table 3).

Conservative or modified abdominopelvic/genitourinary surgery should only be implemented if it does not compromise patient outcome. All patients at risk for infertility who have not completed childbearing should discuss germ cell storage options with the medical team.

Available interventions for male fertility preservation are unlikely to delay cancer treatment. Semen cryopreservation of at least three samples with 48-h abstinence intervals is recommended for men [III, A]. For azoospermic men, testicular sperm extraction may be an option for fertility preservation [V, D]. Prepubertal males may participate in clinical research of testicular tissue/spermatogonial stem cell storage. No studies support the effectiveness of male gonadal protection by means of hormonal manipulations during chemotherapy or radiotherapy.

Female fertility preservation procedures have requirements for scheduling and ovarian stimulation, resulting in a likely

**Table 3.** Risk of female gonadotoxicity of various antineoplastic agents

	High risk (>80%) <sup>a</sup>	Intermediate risk	Low risk (<20%)	Unknown risk	
Single agents	Cyclophosphamide	Anthracyclines	Methotrexate	Taxanes	
	Busulfan	Cisplatin	Bleomycin	Oxaliplatin	
	Melphalan	Carboplatin	5-Fluorouracil	Irinotecan	
	Chlorambucil	Ara-C	Actinomycin-D	Monoclonal antibodies	
	Dacarbazine		Vinca alkaloids	Tyrosine kinase inhibitors	
	Procarbazine		Mercaptopurine		
	Ifosfamide		Etoposide		
	Thiotepa		Fludarabine		
	Combinations and radiation therapy	Nitrogen mustard			
		High-dose cyclophosphamide/ busulfan and hematopoietic stem cell transplantation	CMF, CAF, FEC × 6 in women 30–39 years	ABVD.CMF, FEC, CAF × 6 in women <30 years	
Ovarian irradiation		AC, EC × 4 in women >40 years	CHOP, CVP		
CMF, CAF, FEC × 6 in women >40 years			Protocols for AML, ALL AC × 4 in women <40 years		

<sup>a</sup>Incidence of permanent amenorrhea in exposed women.

delay of 2–6 weeks of cancer treatment initiation. Embryo cryopreservation and ovary transposition are the only established fertility preservation options for female patients, live birth rates being inferior to fresh embryo procedures. Menstrual function resumes in ~50% of women undergoing ovarian transposition, due to ischemia and scatter radiation [III, A]. Short-term ovarian stimulation with gonadotrophins is necessary for oocyte retrieval and may be associated with a theoretical risk of growth of hormone-sensitive tumors. Emerging evidence on alternative (letrozole or tamoxifen) stimulation protocols is scant. Experimental fertility preservation options are oocyte cryopreservation for women without a partner and ovarian tissue storage for those who cannot undergo ovarian stimulation or are prepubertal. Despite >120 deliveries with oocyte storage, issues with oocyte damage, DNA integrity and low yield of pregnancy urge us to consider oocyte cryopreservation experimental. Ovarian tissue reimplantation carries a low risk of reintroduction of cancer cells if ovarian micrometastases were present.

Female gonadal protection from chemotherapy by means of oral contraceptive or GnRH agonist administration was effective in observational studies but should be considered investigational until results of ongoing prospective randomized trials become available [III, B].

Post-hoc subgroup analyses of prospective trials and three meta-analyses showed that amenorrhea induced by chemotherapy or GnRH-agonists, compared with menses preservation, was associated with improved survival in premenopausal women with resected hormone receptor-positive breast cancer. However, permanent amenorrhea had no advantage over a temporary one in terms of patient outcome. These facts should be communicated to the patient with hormone-responsive tumor who is considering preservation of menses.

Aside from the risk of cancer relapse which may require avoidance of childbearing for 2–3 years, all male and female patients who remain fertile after cancer treatment should defer childbearing for at least 12 months to ensure germ cell integrity [IV, C].

Women with a history of cancer/cancer treatment should be considered high risk for perinatal complications (maternal cardiac failure, miscarriage, low birth weight and prematurity of the newborn) and receive specialized, close care. Though poor DNA integrity has been reported in gametes of cancer patients, in the setting of successful fertility preservation/restoration there is no evidence that prior history of cancer or cancer therapy increases the rates of malformations, functional defects or malignancies in the patient’s offspring [V, D].

**note**

Levels of evidence [I–V] and grades of recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the expert authors and the ESMO faculty.

**literature**

1. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: Poena magna, not anymore. *Eur J Cancer* 2006; 42: 126–140.
2. Loibl S, Minckwitz G, Gwyn K et al. Breast carcinoma during pregnancy. International Recommendations from an expert meeting. *Cancer* 2006; 106: 237–246.
3. Mazze R, Kallen B. Reproductive outcome after anesthesia and operation during pregnancy: a registry of 5405 cases. *Am J Obstet Gynecol* 1989; 161: 1178–1185.
4. Nicklas A, Baker M. Imaging strategies in pregnant cancer patients. *Semin Oncol* 2000; 27: 623–632.
5. International Commission on Radiological Protection: biological effects after prenatal irradiation (embryo and fetus). ICRP publication 90. *Ann ICRP* 2003; 33: 5–206.

6. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. *Lancet Oncol* 2004; 5: 283–291.
7. Mir O, Berveiller P, Ropert S et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. *Ann Oncol* 2008; 19: 607–613.
8. Robinson AA, Watson WJ, Leslie KK. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. *Lancet Oncol* 2007; 8: 738–743.
9. Rodriguez AO, Chew H, Rosemary C et al. Evidence of poorer survival in pregnancy-associated breast cancer. *Obstet Gynecol* 2008; 112: 71–78.
10. Petrek JA, Dukoff R, Rogatko A. Prognosis of pregnancy-associated breast cancer. *Cancer* 1991; 67: 869–872.
11. Kroman N, Jensen MB, Wohlfahrt J, Ejlersen B. Pregnancy after treatment of breast cancer—a population-based study on behalf of DBCCG. *Acta Oncol* 2008; 47: 545–549.
12. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: a population based study. *BMJ* 2007; 334: 194.
13. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. *J Clin Oncol* 2006; 24: 5769–5779.
14. Borde F, Chapelle-Marcilac IFP, Hery M et al. Role of chemo-induced amenorrhea in premenopausal, node positive, operable breast cancer patients. Nine-year follow up results of FASG database. *Breast Cancer Res Treat* 2003; 82 (Suppl 1): 30.
15. Cuzick J. The impact of LHRH agonists on breast cancer recurrence and mortality: an overview of the randomized trials. *Breast Cancer Res Treat* 2006; 100 (Suppl 1): S10.
16. Aviles A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. *Clin Lymphoma* 2001; 2: 173–177.
17. Lee SJ, Schover LR, Partridge AH et al. ASCO recommendations on fertility preservation in cancer patients. *J Clin Oncol* 2006; 24: 2917–2931.
18. Gerber B, Dieterich M, Muller H, Reimer T. Controversies in preservation of ovary function and fertility in patients with breast cancer. *Breast Cancer Res Treat* 2008; 108: 1–7.
19. Shin D, Lo KC, Lipshultz LI. Treatment options for the infertile male with cancer. *J Natl Cancer Inst Monogr* 2005; 34: 48–50.
20. Orwig KE, Schlatt S. Cryopreservation and transplantation of spermatogonia and testicular tissue for preservation of male fertility. *J Natl Cancer Inst Monogr* 2005; 34: 51–56.
21. Marthom E, Cohen I. Fertility preservation options for women with malignancies. *Obstet Gynecol Surv* 2006; 62: 58–72.
22. Donnez J, Martinez-Madrid B, Jadoul P et al. Ovarian tissue cryopreservation and transplantation: a review. *Human Reprod Update* 2006; 12: 519–535.